The trust and resources invested in Abzu by our VC partners and the European Innovation Council have been pivotal in scaling our operations and research capabilities.
These investments in Abzu laid the foundation for us to unlock the future with explainable AI.
In a remarkable endorsement of our ethical technology, European values, and our innovations in pharma R&D, Abzu has been honored with an EIC Accelerator Grant at its maximum funding capacity of € 2.5 million.
Pre-seed and seed funding: The power of partnership.
Abzu has raised a total of € 10.2 million in VC funding.
Investment in Abzu is more than financial backing; it’s a belief in our potential to revolutionize disease understanding and drug design with our AI-driven approach.
Thanks to our investors:
One of the most experienced Nordic venture funds, Inventure specializes in helping with talent and expansion.
We are discerning in our selection of investment partners. If you share our vision for unlocking the future of drug development with explainable AI, then please complete the form below to start the conversation.
Entering your information above does not subscribe you to marketing emails from Abzu. It just makes it easier for us to get in touch with you. If you want to subscribe for information from Abzu, you can subscribe here.
Abzu is making headlines.
Abzu's innovative work in AI and pharma R&D makes waves in the scientific community and beyond.
Pharmafocus February 7, 2024
Don’t settle for black box: Why only explainable AI is built for pharma.
IPT June 12, 2023
AI in Pharma: Balancing Reality with Possibility.
Sifted May 5, 2023
20 Nordic startups to watch, according to investors.
OTS May 9, 2022
Could Artificial Intelligence Provide the Key to Life Saving Medicines?